ArticleVaccine2019
Seroprevalence and durability of rubella virus antibodies in a highly immunized population.
Article in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Waning Measles Immunity and Sustained Rubella Seroprotection Among Adults in Istanbul, Türkiye.Medicina (Kaunas, Lithuania) · 2026Article
- Decreasing Antibody Titers and the Slow Decay of Measles Immunity in Mexico's Current Epidemiological Landscape.Vaccines · 2026Article
- Gene Expression Factors Associated with Rubella-Specific Humoral Immunity After a Third MMR Vaccine Dose.Viruses · 2025Article
- The Use of Residual Blood Specimens in Seroprevalence Studies for Vaccine-Preventable Diseases: A Scoping Review.Vaccines · 2025Review
- Serological insights from SARS-CoV-2 heterologous prime and boost responses in Thailand.Scientific reports · 2025Article
- Rubella Seropositivity and Associated Factors Among Young Female Adults in Bangladesh: A Cross-Sectional Study.International journal of general medicine · 2025Article
- [Measles and Rubella IgG Seropositivity in the Post-elimination Era, Costa Rica, 2012-2023Soropositividade de IgG para os vírus do sarampo e da rubéola na era pós-eliminação, Costa Rica, 2012-2023].Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Associations of adaptive immune cell subsets with measles, mumps, and Rubella-Specific immune response outcomes.Heliyon · 2023Article
- Rubella Vaccine Uptake among Women of Childbearing Age in Healthcare Settings.Healthcare (Basel, Switzerland) · 2023Article
- Article
- Transcriptional signatures associated with rubella virus-specific humoral immunity after a third dose of MMR vaccine in women of childbearing age.European journal of immunology · 2021Article
- Rubella Serosurvey Among Future Healthcare Workers.Frontiers in public health · 2021Article
- Article
- Article
- Rubella Immunity among Italian Female Healthcare Workers: A Serological Study.International journal of environmental research and public health · 2020Article
- Article
- Current Challenges in Vaccinology.Frontiers in immunology · 2020Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAlthough the administration of the measles-mumps-rubella (MMR) vaccine has been widespread in the United States for decades, gaps in vaccine coverage still persist for various reasons. The maintenance of herd immunity against rubella virus (RV) is important to controlling the spread and resurgence of rubella and congenital rubella syndrome.
methodsIn this study, we sought to assess the seroprevalence of RV-specific antibodies in an adult population from a defined geographic area in Olmsted County, MN, and the surrounding municipalities, with relatively high vaccine coverage and no documented evidence of circulating RV in the past 24 years. Rubella-specific IgG antibodies were measured by ELISA in a large set of serum samples (n = 1393) obtained from the Mayo Clinic Biobank. This cohort was 80.2% female and ranged from 20 to 44 years of age.
resultsIn total, 97.8% of subjects were seropositive for rubella-specific IgG antibodies, with a median titer of 40.56 IU/mL, suggesting a high degree of immunization; however, 2.2% of subjects were found to be seronegative. Interestingly, 25.1% of subjects were seropositive but had titers lower than 25 IU/mL, indicating either a population of low responders or individuals that could potentially be at risk of waning immunity. No significant associations or differences were found between RV-specific titers and demographic variables such as age, sex, or body mass index (BMI).
conclusionsA high rate of seropositivity for rubella was found among this young adult cohort, but a significant percent of the cohort had lower titers that may indicate poor initial vaccine response and potential risk if their antibody titers decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.